Article
Clearside Biomedical Filed A Voluntary Petition For Bankruptcy
- Intended to Maximize Stakeholder Value Through a Structured Process.
- Validated SCS Microinjector Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations with Future Royalty Revenue Potential.
- CLS-AX TKI Program Includes Phase 3-Ready Asset in Wet AMD and Path for Phase 2b/3 Trial in Diabetic Retinopathy.
- IND-Ready Programs Targeting Geographic Atrophy and Diabetic Macula Edema
Comments
- No comments yet. Be the first to comment!